| Name | Laurels Of Dekalb |
|---|---|
| Location | 520 W Liberty St, Butler, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 101 |
| Occupancy Rate | 74.46% |
| Medicare ID (CCN) | 155386 |
| Legal Business Name | Daviess County Hospital |
| Ownership Type | For Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
A research team led by scientists at Mayo Clinic in Florida have decoded the entire pathway that regulates leakiness of blood vessels — a condition that promotes a wide number of disorders, such as heart disease, cancer growth and spread, inflammation and respiratory distress.
What is the cost of rare diseases such as Friedreich's Ataxia? By analyzing direct and indirect costs of care research in BioMed Central's open access journal Orphanet Journal of Rare Diseases calculated that conservatively this rare disease costs between £11,000 and £19,000 per person per year.
A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients.
Francisco Bonilla is a pastor in Carthage, Missouri, tending to the spiritual needs of the town's growing Latino community. He's also a media personality, broadcasting his voice far beyond the walls of Casa de Sanidad. Bonilla runs a low-power, Spanish-language radio station from the church.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $108404 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.53 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.41 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 49.61 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.8 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.19 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.2 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.12 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.88 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.49 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 83.61 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.27 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 17.32 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 26.8 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.98 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.04 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 55.71 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 86.93 | 82.93 |
News Archive
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
A research team led by scientists at Mayo Clinic in Florida have decoded the entire pathway that regulates leakiness of blood vessels — a condition that promotes a wide number of disorders, such as heart disease, cancer growth and spread, inflammation and respiratory distress.
What is the cost of rare diseases such as Friedreich's Ataxia? By analyzing direct and indirect costs of care research in BioMed Central's open access journal Orphanet Journal of Rare Diseases calculated that conservatively this rare disease costs between £11,000 and £19,000 per person per year.
A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients.
Francisco Bonilla is a pastor in Carthage, Missouri, tending to the spiritual needs of the town's growing Latino community. He's also a media personality, broadcasting his voice far beyond the walls of Casa de Sanidad. Bonilla runs a low-power, Spanish-language radio station from the church.
› Verified 4 days ago